Is Biomarin Pharmaceutical Inc (BMRN) overvalued? · P/E 40, rev $2.85B
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
This page asks whether Biomarin Pharmaceutical Inc (BMRN) looks expensive on cached numbers — not a short thesis.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BMRN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BMRN stock page for the full model, not this heading.
Not investment advice.